Q3 2026 13F · SEC CIK 2143027

Pavaki Capital Management LLC

Hedge fundFiled 2026-10-26 for Q3 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $199.9M
Reported positions: 132
Holdings vs S&P 500, 3 yrs: —
Assets under management: $410.1M

Pavaki Capital Management LLC is a hedge fund that reported 132 positions worth $199.9M in its Q3 2026 13F, filed 2026-10-26. Its largest holdings were Nvidia Corporation (NVDA, 14.9%), Chevron Corporation (CVX, 10.5%), Intuit (INTU, 5.3%).

Pavaki Capital Management LLC holdings largest 50 of 132 positions.

Weights are shares of the filer's total reported 13F value, compared with Q2 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Pavaki Capital Management LLC 13F holdings
Stock	% of 13F value	Q2 2026	Shares	Share change	Reported value
NVDANvidia Corporation	14.9%	3.0%	130,000	+400.0%	$29.7M
CVXChevron Corporation	10.5%	9.2%	103,000	+6.2%	$21.0M
INTUIntuit	5.3%	5.7%	38,600	+0.0%	$10.6M
BBarrick Mng Corp	4.6%	4.6%	226,500	+2.3%	$9.2M
QCOMQualcomm Inc	4.5%	5.2%	49,000	+0.0%	$9.0M
REGNRegeneron Pharmaceuticals	4.3%	3.5%	11,300	+14.1%	$8.6M
MISTMilestone Pharmaceuticals in	4.0%	6.9%	9,337,848	+3.0%	$8.1M
TXTTextron Inc	3.5%	4.4%	90,800	+7.7%	$6.9M
BTGB2gold Corp	3.1%	2.5%	1,180,000	+0.0%	$6.2M
ARQTArcutis Biotherapeutics Inc	2.5%	2.8%	187,000	+0.0%	$4.9M
MUMicron Technology Inc	2.1%	2.6%	4,000	+0.0%	$4.3M
CGAUCenterra Gold Incorporated (canada)	1.9%	1.8%	177,000	-10.2%	$3.9M
NEMNewmont Corp	1.9%	1.7%	32,500	+0.0%	$3.7M
LGNDLigand Pharmaceuticals Inc	1.7%	2.0%	11,100	+0.0%	$3.5M
SLBSlb Limited	1.5%	1.6%	61,000	+0.0%	$3.0M
HRMYHarmony Biosciences Holdings I	1.4%	1.5%	73,000	+0.0%	$2.9M
SPRYArs Pharmaceuticals Inc	1.4%	2.6%	659,600	+13.8%	$2.8M
RPRXRoyalty Pharma PLC	1.3%	1.4%	44,000	+0.0%	$2.6M
BIOBio Rad Labs Inc	1.1%	1.0%	6,000	+0.0%	$2.3M
PSKYParamount Skydance Corp	1.1%	1.2%	208,863	+0.0%	$2.2M
EWSIshares Inc Msci Singpor	1.0%	1.0%	60,000	+0.0%	$2.0M
FSKFs Kkr Capital Corp	1.0%	1.0%	180,100	+12.5%	$2.0M
SSRMSsr Mng Inc	0.9%	1.2%	53,000	-29.3%	$1.8M
NAMSNewamsterdam Pharma Company Ordinary	0.8%	1.3%	66,600	+0.0%	$1.6M
DOUGDouglas Elliman Inc	0.8%	1.0%	1,022,552	+0.0%	$1.6M
HALHalliburton Co	0.7%	0.9%	46,000	+0.0%	$1.5M
EPHEIshares Tr Msci Philips	0.7%	0.8%	58,000	+0.0%	$1.3M
YUMCYum China Hldgs Inc	0.6%	0.7%	30,000	+0.0%	$1.2M
KGCKinross Gold Corp	0.6%	0.7%	49,500	+0.0%	$1.2M
BIDUBaidu Inc	0.6%	0.8%	13,000	+0.0%	$1.1M
SNDXSyndax Pharmaceuticals Inc	0.6%	0.7%	60,000	+0.0%	$1.1M
OCANFOceanagold Corporation Com New (canada)	0.6%	0.6%	40,200	+0.0%	$1.1M
EQXEquinox Gold Corp	0.5%	0.6%	91,000	-9.0%	$1.0M
RMRRmr Group Inc.	0.5%	—	55,500	—	$1.0M
BBDBanco Bradesco S A Sp	0.5%	0.5%	264,336	+0.0%	$930K
UBSUbs Group AG	0.5%	0.5%	19,000	+0.0%	$916K
ERICEricsson	0.4%	0.6%	97,500	+0.0%	$892K
RGLDRoyal Gold Inc	0.4%	0.4%	3,750	+0.0%	$885K
OSUROrasure Technologies Inc	0.4%	0.6%	219,033	+0.0%	$859K
ICLRIcon Plc	0.4%	0.5%	5,000	+0.0%	$850K
SNYNFSanofi SA	0.4%	0.5%	20,000	+0.0%	$825K
BKRBaker Hughes Company Cl A	0.4%	0.5%	15,000	+0.0%	$824K
KSPIKaspi Kz Jsc	0.4%	0.4%	8,700	+0.0%	$818K
BIIBBiogen Inc	0.4%	0.4%	3,500	+0.0%	$791K
MRKMerck & Co Inc	0.4%	—	5,000	—	$727K
LNTHLantheus Hldgs Inc	0.4%	0.4%	7,100	+0.0%	$707K
KBRKbr Inc	0.4%	—	20,000	—	$703K
ITUBItau Unibanco Hldg S A	0.4%	—	82,400	—	$703K
CLBTCellebrite Di Ltd	0.3%	0.5%	60,000	+0.0%	$676K
DHCDiversified Healthcare Tr	0.3%	0.5%	85,000	+0.0%	$667K

What Pavaki Capital Management LLC bought and sold in Q3 2026, against Q2 2026.

New positions

Q2 2026's filing was too long to tell new positions apart.

Added to

NVDA Nvidia Corporation+400.0% shares
REGN Regeneron Pharmaceuticals+14.1% shares
SPRY Ars Pharmaceuticals Inc+13.8% shares
FSK Fs Kkr Capital Corp+12.5% shares
TXT Textron Inc+7.7% shares
CVX Chevron Corporation+6.2% shares

Reduced

SSRM Ssr Mng Inc-29.3% shares
CGAU Centerra Gold Incorporated (canada)-10.2% shares
EQX Equinox Gold Corp-9.0% shares

Left the top 50

Share counts compared with the Q2 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: —
3 years: —
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q3 2026	$199.9M	132
Q2 2026	$175.5M	132
Q1 2026	$142.3M	121

Questions about Pavaki Capital Management LLC's portfolio

What stocks does Pavaki Capital Management LLC own?

Pavaki Capital Management LLC's latest 13F, for Q3 2026 and filed Oct 26, 2026, lists 132 positions worth $199.9M. The largest are Nvidia Corporation (NVDA) at 14.9%, Chevron Corporation (CVX) at 10.5%, Intuit (INTU) at 5.3%, Barrick Mng Corp (B) at 4.6% and Qualcomm Inc (QCOM) at 4.5%.

What did Pavaki Capital Management LLC buy last quarter?

In Q3 2026, Pavaki Capital Management LLC added Nvidia Corporation (NVDA) (+400.0% shares), Regeneron Pharmaceuticals (REGN) (+14.1% shares) and Ars Pharmaceuticals Inc (SPRY) (+13.8% shares), compared with its Q2 2026 filing.

What did Pavaki Capital Management LLC sell last quarter?

In Q3 2026, Pavaki Capital Management LLC cut from its top 50 Advanced Micro Devices Inc (AMD), cut from its top 50 Nokia Corp (NOK), cut from its top 50 Replimune Group Inc (REPL), cut from its top 50 Kodiak Gas Svcs Inc (KGS), Ssr Mng Inc (SSRM) (-29.3% shares), Centerra Gold Incorporated (canada) (CGAU) (-10.2% shares) and Equinox Gold Corp (EQX) (-9.0% shares), compared with its Q2 2026 filing.

When is Pavaki Capital Management LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Pavaki Capital Management LLC's filing for the quarter ending Dec 31, 2026 is due by Feb 14, 2027; this page updates the day after it is published.

How much money does Pavaki Capital Management LLC manage?

Pavaki Capital Management LLC reported $410.1M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $199.9M.